Farxiga Pharmacokinetics (ADME): How Dapagliflozin Is Absorbed, Distributed, Metabolized, and Eliminated

Mechanism of Action: What Dapagliflozin Does Before ADME Matters

Dapagliflozin works by selectively blocking the sodium-glucose cotransporter 2 (SGLT2) protein in the S1 segment of the proximal renal tubule. This transporter normally reabsorbs about 90% of the glucose filtered by the kidneys. Blocking it forces the kidneys to excrete excess glucose into the urine [1].

SGLT2 Selectivity

Dapagliflozin's selectivity for SGLT2 over SGLT1 is approximately 1,200-fold [2]. This matters because SGLT1 handles glucose absorption in the gut and residual glucose reabsorption in the S3 segment of the tubule. A drug that hit both transporters equally would cause significant GI side effects. Dapagliflozin's high selectivity ratio explains its relatively clean gastrointestinal tolerability profile compared to less selective agents.

Beyond Glucose: The Natriuretic and Hemodynamic Effects

The pharmacologic action extends past glycosuria. SGLT2 inhibition causes a mild osmotic diuresis (roughly 375 mL/day of additional urine volume) and natriuresis, reducing plasma volume and cardiac preload [3]. This mechanism underpins the cardiovascular and renal benefits observed in the DAPA-HF trial (N=4,744), where dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74; 95% CI, 0.65 to 0.85; P<0.001) versus placebo in patients with HFrEF [4]. The hemodynamic effects begin within hours of dosing, a timeline directly connected to the drug's absorption kinetics.

Absorption: Rapid Oral Uptake With High Bioavailability

Dapagliflozin is rapidly absorbed after oral administration. The absolute oral bioavailability of a 10 mg dose is 78% [1]. Peak plasma concentrations (Cmax) typically occur within 2 hours under fasting conditions.

Food Effects on Absorption

A high-fat meal slows absorption but does not reduce total drug exposure in a clinically meaningful way. Specifically, a high-fat breakfast delays Tmax by approximately 1 hour and reduces Cmax by 26%, but total exposure (AUC) decreases by only 6% [1]. The FDA label permits dosing with or without food, reflecting this negligible AUC change.

Dose Proportionality

Plasma concentrations increase proportionally across the 0.1 mg to 500 mg dose range studied in Phase 1, which comfortably brackets the approved 5 mg and 10 mg clinical doses [2]. This linear pharmacokinetics means that doubling the dose doubles the plasma exposure, a property that simplifies titration decisions in practice.

Distribution: Protein Binding and Tissue Penetration

After absorption, dapagliflozin distributes into a volume of approximately 118 liters at steady state, indicating moderate extravascular distribution beyond plasma [1].

Plasma Protein Binding

Dapagliflozin is roughly 91% bound to plasma proteins, predominantly albumin [1]. This binding is independent of concentration across the therapeutic range and is not meaningfully altered in patients with renal or hepatic impairment. For clinicians, the key implication is that dapagliflozin's displacement from albumin by co-administered highly protein-bound drugs is unlikely to cause clinically relevant changes in free-drug concentration.

Partitioning Into Red Blood Cells

The mean blood-to-plasma concentration ratio is 0.88, indicating that dapagliflozin does not preferentially partition into red blood cells [2]. This simplifies pharmacokinetic sampling because plasma drug levels reliably approximate whole-blood concentrations.

Metabolism: UGT1A9, Not CYP450

The metabolic pathway of dapagliflozin is one of its most clinically important pharmacokinetic features. The drug is primarily metabolized by uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9), producing an inactive metabolite called dapagliflozin 3-O-glucuronide [1].

Why UGT1A9 Matters Clinically

Most oral medications used in cardiometabolic disease (statins, warfarin, certain antihypertensives) are metabolized through cytochrome P450 enzymes. Dapagliflozin largely bypasses this system. CYP-mediated oxidative metabolism is a minor pathway; no single CYP isoform contributes more than a small fraction to total clearance [2]. This means dapagliflozin carries a low risk of pharmacokinetic drug-drug interactions with the hundreds of CYP3A4, CYP2C9, and CYP2D6 substrates and inhibitors commonly prescribed alongside it.

The Inactive Glucuronide Metabolite

Dapagliflozin 3-O-glucuronide is the major circulating metabolite, accounting for approximately 61% of the administered dose. It has no pharmacologic activity against SGLT2 [1]. This is significant: even if glucuronide hydrolysis were to regenerate the parent compound in certain tissues, the net contribution to SGLT2 inhibition from metabolite recycling appears negligible.

Drug-Drug Interaction Profile

Formal interaction studies confirm the low-risk profile:

• Metformin: No clinically significant pharmacokinetic changes in either direction when co-administered [1].
• Pioglitazone: Co-administration does not alter dapagliflozin exposure [1].
• Sitagliptin: No meaningful effect on dapagliflozin AUC or Cmax [1].
• Glimepiride: No change in dapagliflozin pharmacokinetics [1].
• Valsartan: Co-administration is pharmacokinetically neutral [1].
• Simvastatin: Dapagliflozin did not affect simvastatin AUC; simvastatin did not alter dapagliflozin exposure [1].
• Warfarin: No effect on S-warfarin exposure or INR [1].
• Rifampin (a potent UGT/CYP inducer): Reduced dapagliflozin AUC by 22%, which the FDA deemed not clinically significant enough to require dose adjustment [1].
• Mefenamic acid (a UGT1A9 inhibitor): Increased dapagliflozin AUC by 51%, but no dose adjustment is recommended in the label [1].

This profile is particularly favorable for the polypharmacy-heavy populations that receive dapagliflozin (patients with type 2 diabetes, heart failure, or chronic kidney disease who often take 8 to 12 concomitant medications).

Excretion: Renal-Dominant Clearance of Inactive Metabolites

After a single 50 mg oral dose of [14C]-dapagliflozin, approximately 75% of total radioactivity was recovered in urine and 21% in feces [1].

Renal Handling of Parent Drug vs. Metabolite

The kidney excretes the drug primarily as the inactive 3-O-glucuronide metabolite. Less than 2% of the administered dose appears in urine as unchanged dapagliflozin [1]. This distinction is critical for understanding performance in renal impairment: the pharmacologic action of dapagliflozin occurs at the luminal brush border of the proximal tubule (a pre-excretory site), so systemic drug clearance rates and urinary metabolite recovery are partially decoupled from the drug's glucose-lowering effect.

Terminal Half-Life and Steady-State Kinetics

The mean terminal elimination half-life is 12.9 hours after a single 10 mg oral dose in healthy subjects [1]. Steady-state concentrations are reached within 3 days of once-daily dosing, with a modest accumulation ratio of about 1.12 [2]. The 12.9-hour half-life explains why once-daily dosing provides sustained 24-hour SGLT2 inhibition: even at trough (24 hours post-dose), plasma concentrations remain above the IC50 for SGLT2 blockade.

Special Populations: How PK Changes With Organ Impairment

Dapagliflozin's pharmacokinetics shift in predictable ways across subpopulations defined by renal function, hepatic function, age, and body weight.

Renal Impairment

In a dedicated renal impairment study, mean AUC at steady state increased by approximately 32% in mild impairment (eGFR 60 to 89 mL/min/1.73 m²), 60% in moderate impairment (eGFR 30 to 59), and 87% in severe impairment (eGFR <30) compared with normal renal function [1]. Despite these exposure increases, glycosuric efficacy decreases in parallel with declining GFR because less glucose is filtered for SGLT2 to act upon. The DAPA-CKD trial (N=4,304) demonstrated that dapagliflozin reduced the risk of sustained eGFR decline of 50% or greater, end-stage kidney disease, or renal or cardiovascular death by 39% (HR 0.61; 95% CI, 0.51 to 0.72; P<0.001) in patients with CKD regardless of diabetes status, supporting its use down to eGFR 25 mL/min/1.73 m² [5].

Hepatic Impairment

Mild hepatic impairment (Child-Pugh A) does not meaningfully alter exposure. Moderate impairment (Child-Pugh B) increases mean Cmax by 12% and AUC by 36% [1]. Dapagliflozin has not been studied in severe hepatic impairment (Child-Pugh C) and is not recommended in that population.

Age, Sex, Race, and Body Weight

Population pharmacokinetic analyses show no clinically relevant differences by age (18 to 80 years), sex, race, or body weight that would require dose modification [1]. In patients aged 65 and older, mean AUC is approximately 8% higher than in younger adults, a difference well within normal interindividual variability [2].

Clinical Pharmacodynamics: Linking PK to Glucose Excretion

Urinary Glucose Excretion as a PD Marker

After a single 10 mg dose in healthy subjects, 24-hour urinary glucose excretion (UGE) increases by approximately 70 grams [2]. At steady state in patients with type 2 diabetes, daily UGE reaches approximately 60 to 80 grams, corresponding to roughly 240 to 320 kcal of caloric loss per day [6]. This caloric deficit contributes to the modest weight loss (typically 2 to 3 kg) seen in clinical trials.

Duration of SGLT2 Inhibition

SGLT2 occupancy studies using the renal glucose reabsorption technique show that a 10 mg dose inhibits approximately 50 to 60% of filtered glucose reabsorption over 24 hours [2]. Maximal inhibition occurs at 2 to 4 hours post-dose, coinciding with Tmax. Even at 24 hours, meaningful inhibition persists, confirming that the 12.9-hour half-life delivers adequate trough coverage. This is the pharmacokinetic basis for once-daily dosing without a second daily dose.

HbA1c and the Exposure-Response Relationship

In a pooled analysis of Phase 3 data, dapagliflozin 10 mg produced mean HbA1c reductions of 0.5% to 0.7% from baseline across monotherapy and add-on studies [7]. The exposure-response curve plateaus near the 10 mg dose; increasing to 20 mg or 50 mg in Phase 1 studies produced only marginal additional glucose excretion, which is why the clinical program settled on 5 mg and 10 mg [2].

Practical Dosing Implications From the PK Profile

The pharmacokinetic profile of dapagliflozin translates into several concrete prescribing considerations. The 78% oral bioavailability and linear dose proportionality mean that the administered dose closely predicts systemic exposure. Once-daily dosing in the morning is standard, though the flat food-effect data means timing relative to meals is flexible. No dose adjustment is needed for mild to moderate renal impairment, mild to moderate hepatic impairment, or any combination of age, sex, race, or body weight within studied ranges. The UGT1A9-dominant metabolism minimizes CYP450-mediated drug interactions, which simplifies co-prescribing in patients taking statins, ACE inhibitors, ARBs, or oral anticoagulants. Rifampin co-administration reduces exposure by 22%, and mefenamic acid increases it by 51%, but neither interaction triggers a formal dose adjustment per the FDA label [1].